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Abstract
Background Pre-/postoperative pituitary endocrine deficiencies in patients with sellar/parasellar non-adenomatous lesions are
poorly described and studies have not considered the effect of sellar invasion on endocrine outcome. The aim of this study was to
relate the need for pituitary hormone replacement pre-/postoperatively, with sellar invasion, in non-adenomatous sellar/parasellar
lesions.
Methods Single-centre review of adults with histologically confirmed non-adenomatous sellar/parasellar lesion and follow-up ≥
3 months or until postop radiotherapy. Pituitary dysfunction was defined by hormone replacement. The sellar encroachment
score (0–6) was calculated as the sum of the thirds of radiological encroachment into the sellar region in the coronal and sagittal
planes. Multivariate analysis with binary logistic regression was used to determine factors associated with pituitary hormone
replacement.
Results One hundred and seventeen patients were included with a median age of 49 years (range 16–84 years) and median
follow-up of 13 months. Surgery was trans-sphenoidal (53%), trans-cranial (36%) or a combination (11%). The commonest
histology types were meningioma (n = 33, 28%) and craniopharyngioma (n = 20, 17%). The median sellar encroachment score
was 6 (range 0–6). Most (n = 86, 74%) did not require pituitary hormone replacement preoperatively. The need for pituitary
hormones increased after surgery in 41 (35%) patients. In multivariate analysis, the sellar encroachment score was the only factor
predictive of pre- (OR = 2.6, 95% CI = 1.2–5.5; p = 0.01) and postoperative risk of new pituitary hormone replacement (OR =
4.1, 95% CI = 1.7–10.1, p = 0.002).
Conclusion A significant proportion of these patients present with need for pituitary hormone replacement that may worsen
postoperatively. The degree of sellar encroachment is predictive of pituitary hormone replacement status pre-/postoperatively.
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Introduction
Patients with sellar region lesions can present with hypopitu-
itarism. However, endocrine outcomes are best described for
the subgroup of pituitary adenomas, which constitute over
90% of the lesions in this area [13]. The remaining 10% of
patients harbour other non-adenomatous pathology, which
can range from other tumour subtypes (e.g. meningiomas) to
cysts, vascular malformations, inflammatory processes and
infection [13]. There is a sparsity of literature describing out-
comes in this group, especially those related to pituitary endo-
crine function. This is important as hypopituitarism has previ-
ously been identified as an independent predictor of mortality
[12]. Outcome data can help guide clinicians as to which pa-
tients at presentation need screening for pituitary dysfunction
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at presentation, and communicate the risk of hypopituitarism
with surgery, particularly for those patients with sellar/
parasellar pathology types at risk of requiring postop hormone
replacement.
Studies to data describing outcomes in non-adenomatous
sellar/parasellar lesions have reported conflicting findings [2,
3, 8]. This is for a variety of reasons. Some studies have
restricted their inclusion criteria and reported on the
commonest histology types encountered in this region, whilst
others have focussed on the rarest [3, 8]. The majority have
also not controlled for the effects of radiotherapy, which can
cause irreversible and progressive pituitary dysfunction [2].
Other important considerations include the lesion size, the
extent of resection and potentially the degree of encroachment
of the lesion into the pituitary fossa.
The aim of the present study was to present pituitary endo-
crine outcomes as assessed by need for pituitary hormone
replacement in a large cohort of non-adenomatous lesions of
the sellar/parasellar region. We accounted for postoperative
radiotherapy use and also considered the degree of sellar en-
croachment by developing a novel scoring system.
Methods
This single-centre study was registered locally and approved
by the institutional review board. Ethical approval, patient
consent and funding were not required for this study design.
Data collection
Adult (≥ 16 years) patients with histologically confirmed non-
adenomatous sellar and parasellar lesions were identified from
a prospective pituitary database operated on by a single sur-
geon (2006–2018). Follow-up was defined as the time interval
between surgery and the last clinic appointment, or in the case
of patients undergoing postoperative radiotherapy, the last
clinic appointment before delivery of radiotherapy.
Data was collected on patient demographics, MRI charac-
teristics, histology, treatment and pituitary hormone status
preoperatively and at last follow-up. Histology types were
grouped as in previous studies [2, 3, 8]. All patients had pre-
and postoperative baseline pituitary hormone profile assessed
by the endocrine team. Postoperative tests included dynamic
assessment (i.e. glucagon stress test) of pituitary hormone se-
cretion. Pituitary hormone status was recorded prior to com-
mencement of postoperative radiotherapy where applicable.
Pituitary dysfunction was defined in terms of replacement
hormone required for each key pituitary hormone axis—
glucocorticoids (ACTH), thyroxine (TSH), growth hormone
(GH) and desmopressin (ADH).With respect to gonadotrophs
and sex hormones, we took note of replacement with testos-
terone and oestrogen/progesterone.
Imaging review
Preoperative MRI scans were reviewed by SR and DB to
determine lesion volume as described previously
(4/3 × : × radius3) [14].
The degree of encroachment into the pituitary fossa in the
sagittal and coronal planes was assessed using the sellar en-
croachment score (Fig. 1a). The sellar encroachment score (0–
6) represented the sum of the number of thirds of sellar en-
croachment in the coronal (Fig. 1a left panel) and sagittal
planes (Fig. 1a right panel). Sellar encroachment can be from
any direction, but in this figure it is drawn in an advancing
manner from right to left and anterior to posterior directions. A
score of 0 indicates no encroachment into the sellar floor.
Serial postoperative MRI scans were also reviewed to de-
termine the extent of resection: biopsy (≤ 10%), subtotal (10–
90%) and near total (i.e. > 90%; no obvious remnant evident).
The sellar encroachment score (0–6) represented the sum of
the number of thirds of sellar encroachment in the coronal
(Fig. 1a left panel) and sagittal planes (Fig. 1a right panel).
Sellar encroachment can be from any direction and a score of
0 indicates no encroachment into the sellar floor.
Serial postoperative MRI scans were also reviewed to de-
termine the extent of resection: biopsy (≤ 10%), subtotal (10–
90%) and near total (i.e. > 90%; no obvious remnant evident).
Statistics
Statistical analysiswas performed usingSPSSversion 22 (SPSS
Inc., Chicago, IL, USA). Categorical variables were compared
using tests of proportions (Fisher’s exact, chi-squared). Inter-
rater reliability was performed using the intraclass correlation
coefficient indicating a good level of agreement (ICC = 0.74).
Fig. 1 Sellar encroachment score. a The total score is the sum of the
thirds of sellar encroachment in the coronal (left panel) and sagittal
(right panel) planes. For each plane, imaginary lines parallel to the
pituitary stalk dividing the sellar into thirds are considered. Sellar
encroachment can be from any direction, but in these figures it is drawn
in an advancing manner from the left to right and anterior to posterior
directions. A score of 0 indicates no encroachment into the sellar floor. b
A27-year-old female with an incidental left cavernous lesion underwent a
trans-sphenoidal biopsy and later a craniotomy for a left temporal fossa
chondrosarcoma. She did not require any pituitary hormone replacement
pre- or postoperatively. c A 77-year-old male with left-sided visual field
deficits underwent trans-nasal resection of a tuberculum sellar meningio-
ma (WHO grade 1). Pre- and postoperatively the patient was on thyroxine
for primary hypothyroidism. d A 70-year-old male presented with diplo-
pia and left-sided ptosis and underwent trans-sphenoidal resection of a
large sellar region chordoma. Preoperatively the patient required hydro-
cortisone and thyroxine with additional need for testosterone postopera-
tively. e A 20-year-old female presented with headaches and blurred
vision. A suprasellar lesion with associated prepontine cyst was debulked
via a craniotomy with insertion of Ommaya reservoir into the prepontine
cyst. Histology was consistent with craniopharyngioma. Preoperatively,
the patient did not require any hormone replacement. Postoperatively, she
required thyroxine
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Multivariate analysis using binary logistic regression was per-
formed to determine factors associated with need for preopera-
tive pituitary hormone replacement and development of addi-
tional pituitary hormones postoperatively. Variables were in-
cluded in the multivariate model where p ≤ 0.1 at the univariate
level. In multivariate analysis, each variable was given with an
odds ratio (OR) and 95% confidence interval (CI).
Results
One hundred nineteen patients were originally identified
from our database and 2 were excluded due to loss to fol-
low-up. One hundred seventeen patients were therefore in-
cluded in this study. The median age was 49 years (range
16–84 years; mean age 50 years). There was a slight female
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excess (M:F, 51:66). The median follow-up was 13 months
(range 1–117 months; mean 24 months) and the endocrine
status was noted before radiotherapy if applicable. Baseline
demographic and treatment characteristics are shown in
Table 1.
The surgical approach was either trans-sphenoidal (N = 62,
53%), craniotomy (N = 42, 36%) or a combination of these
(N = 13, 11%). Radiotherapy was administered postoperative-
ly in 37 (32%) patients. The median number of operations
before radiotherapy was 1 (range 1–4) in 92/117 patients
(79%). Based on the serial postoperative MRI scans, the ex-
tent of surgical resection was considered to be a biopsy (N =
10, 9%), subtotal resection (N = 66, 56%) or near total resec-
tion (N = 41, 35%).
The commonest histology types were meningioma (N = 33,
28%), craniopharyngioma (N = 20, 17%) and Rathke’s cyst
(N = 9, 8%). Other neoplasms encountered included
chordoma (N = 6, 5%), chondrosarcoma (N = 7, 6%), metas-
tases (N = 2, 2%), schwannoma (N = 1, 1%), astrocytoma
(N = 2, 2%) and myeloma (N = 1, 1%). Vascular lesions were
rare, with two cases of cavernoma (2%) and one haematoma
(1%). Cystic lesions included dermoid cysts (N = 1, 1%), epi-
dermoid cysts (N = 2, 2%), pituitary cysts (N = 1, 1%) and
meningoencephalocele (N = 5, 4%). No histological diagnosis
was reached in four cases (4%).
The median lesion volume was 4.19 cm3 (range 0.07–
64.2 cm3, mean 7.33 cm3) and the median sellar encroachment
score was 6 (range 0–6, mean 5) (Table 1).
Endocrine outcomes pre- and postoperatively are shown in
Table 2. Preoperatively, most patients (N = 86, 74%) did not
require pituitary hormone replacements. No patient had
panhypopituitarism preoperatively. Preoperatively in patients
needing at least one pituitary hormone replacement (N = 31,
26%), the most common pituitary hormone replacements were
thyroxine (N = 23) and glucocorticoids (N = 20).
Postoperatively, additional new pituitary hormone replace-
ment was required in 41/117 (35%) patients (Table 2). This
usually manifested as one additional pituitary hormone (N =
24/41, 59%). The commonest new postoperative hormone
replacements were glucocorticoids (N = 23/41, 56%) or thy-
roxine (N = 19/41, 46%). A minority (N = 4/41, 3%) of pa-
tients required fewer hormones after surgery. These 4 patients
were on glucocorticoids preoperatively that was not required
after surgery.
Preoperatively, multivariate analysis was undertaken to de-
termine factors associated with the need for pituitary hormone
replacement (Table 3). Only the sellar encroachment score
was associated with preoperative pituitary hormone replace-
ments on uni- and multivariate analysis (OR 2.6; 95% CI =
1.2–5.5; p = 0.01).
Postoperatively, multivariate analysis was undertaken to
determine factors associated with the need for additional
new pituitary hormone replacements (Table 4). On univariate
analysis, the extent of surgical resection (p = 0.019), histology
(p < 0.001) and sellar encroachment score (p < 0.001) were
associated with new postoperative pituitary hormone replace-
ments. With respect to histology, craniopharyngiomas had
higher (15/20, 75%) rates of requiring new postoperative pi-
tuitary hormone replacements compared with meningiomas
12/33 (36%) and Rathke’s cysts 3/9 (33%). In multivariate
analysis, only the sellar encroachment score remained signif-
icant on multivariate analysis (OR 4.1; 95% CI = 1.7–10.1;
p < 0.002).
Table 1 Patient baseline demographic and treatment characteristics
N 117













Extent of surgical resection
Biopsy 10 (9%)
Subtotal resection 66 (56%)







Rathke’s cyst 9 (8%)
Inflammatory/infective lesion 10 (9%)
Other neoplasm (e.g. chordoma, metastasis, glioma) 25 (21%)
Cystic lesions (dermoid, epidermoid, pituitary cyst,
meningoencephalocele)
12 (10%)
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Table 2 Pre- and postoperative
pituitary hormone replacements
(N = 117). NA, not applicable
Preoperative (N = 117) Postoperative (N = 117)
Number of pituitary hormone replacements
0 86 (74%) 59 (50%)
1 17 (15%) 26 (22%)
2 7 (6%) 11 (9%)
3 6 (5%) 9 (8%)
4 1 (1%) 11 (9%)
5 0 (0%) 1 (1%)
Change in number of pituitary hormone replacements postsurgery
Unchanged NA 72 (62%)
Reduced NA 4 (3%)
Increased NA 41 (35%)
Types of pituitary hormone replacements required
N, ≥ 1 axis pituitary hormones 31 58
Glucocorticoids 20/31 (65%) 39/58 (67%)
Thyroxine 23/31 (74%) 42/58 (72%)
Growth hormone 1/31 (3%) 9/58 (16%)
Sex hormones 4/31 (13%) 22/58 (38%)
Desmopressin 5/31 (16%) 13/58 (22%)
New pituitary hormone replacements required postoperatively
N NA 41
Glucocorticoids NA 23/41 (56%)
Thyroxine NA 19/41 (46%)
Growth hormone NA 8/41 (20%)
Sex hormones NA 18/41 (44%)
Desmopressin NA 8/41 (20%)
Table 3 Multivariate analysis of
factors associated with need for
preoperative pituitary hormone
replacements (N = 31/117; 26%).
Binary logistic regression
revealed the sellar encroachment
score to be the only factor
predictive of this outcome
Factor Preop pituitary hormone
replacement (N, %)
Univariate analysis Multivariate analysis
Age
≤ 49 14/59 (24%) Fisher’s exact,
p = 0.54
Not included
> 49 17/58 (29%)
Gender





Meningioma 7/33 (21%) Chi-squared = 2.94,
p = 0.4
OR = 1.18, 95%




≤ 4.19 mm3 15/60 (25%) Fisher’s exact,
p = 0.8
OR = 1.09, 95%
CI = 0.46–2.61, p = 0.84> 4.19 mm3 16/57 (28%)
Sellar encroachment score
0–2 2/23 (9%) Chi-squared = 6.5,
p = 0.039
OR = 2.57, 95%
CI = 1.21–5.46, p = 0.013–4 2/13 (15%)
5–6 27/81 (33%)
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Figure 1b–e illustrate typical patient examples with differ-
ing levels of encroachment into the sellar region and the re-
spective pituitary hormone outcomes.
Figure 2 shows a visual representation of need for pituitary
hormone replacement pre- and postoperatively in relation to
the sellar encroachment score.
Discussion
Patients with sellar region pathology can present with hypo-
pituitarism which is important to identify given its association
with increased morbidity and mortality [12]. In addition,
assessing the rate of pituitary dysfunction in such cases is
important to guide selection for preoperative pituitary
hormone screening and inform patients of the endocrine risks
of surgery.
In this single-centre study, we described endocrine out-
comes via pituitary hormone replacement in adults with non-
adenomatous sellar/parasellar lesions undergoing trans-
sphenoidal and/or trans-cranial procedures after a median
follow-up of 13 months. More than half (56%) of patients
had lesions completely encroaching into the sella in the coro-
nal and sagittal imaging planes preoperatively, though almost
three-quarters (74%) did not require pituitary hormone re-
placement preoperatively. Pituitary status was assessed post-
operatively at last follow-up and prior to any radiotherapy,
where applicable. A wide variety of pathology subtypes were
included. About one-third of patients (35%) required new pi-
tuitary hormone replacements postoperatively and a minority
(3%) had improved pituitary function. Postoperative
Table 4 Multivariate analysis of
factors associated with need for
new pituitary hormone
replacements postoperatively
(N = 41/117; 35%). Binary
logistic regression revealed the
sellar encroachment score to be
the only factor predictive of this
outcome
Factor New postop pituitary hormone
replacements (N, %)
Univariate analysis Multivariate analysis
Age
≤ 49 21/59 (36%) Fisher’s exact,
p > 0.99
Not included
> 49 20/58 (34%)
Gender





Biopsy 1/10 (10%) Chi-squared = 7.9,
p = 0.019
OR = 0.55, 95%
CI = 0.24–1.22,
p = 0.14




Number of operations pre-radiotherapy
1 34/92 (37%) Fisher’s exact,
p = 0.48
Not included
> 1 7/25 (28%)
Surgical approach
Trans-sphenoidal 17/62 (27%) Chi-squared = 3.6,
p = 0.17






Meningioma 12/33 (36%) Chi-squared = 19.5,
p < 0.001







≤ 4.19 mm3 20/60 (33%) Fisher’s exact,
p = 0.7
Not included
> 4.19 mm3 21/57 (37%)
Sellar encroachment score
0–2 1/23 (4%) Chi-squared = 16.7,
p < 0.001
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deterioration in pituitary function usually manifested as one
additional hormone requirement. In multivariate analysis, the
sellar encroachment score emerged as the only significant fac-
tor predictive of the need for pre- and postoperative new pitu-
itary hormone replacements.
The rate of hypopituitarismwould be expected to be lower in
non-adenomatous lesions compared with adenomas, which in-
trinsically involve the pituitary gland. This is exemplified in
existing literature and in two large series of pituitary adenomas
with 444 and 721 patients, hypopituitarism was noted in 70–
86% of patients at presentation [4, 6]. This compares with rates
of 26–60% in non-adenomatous case series including ours (see
Table 5) [3, 5, 8, 11, 13]. Although the rate of hypopituitarism
may be lower for non-adenomatous lesions of the sellar/
parasellar region, it is still significant and requires pre- and post-
operative screening and appropriate patient counselling.
The rate of new pituitary hormone replacement postopera-
tively (35%) was relatively high in our study compared with
others. This could be due to several reasons. Firstly, more than
half of our patients had complete encroachment of the sella
radiologically preoperatively. Other studies have not reported
lesion size or sellar encroachment characteristics and may have
included predominantly smaller lesions not fully involving the
sella region. Secondly, unlike the present study, several other
studies have excluded histology types associated with higher
rates of hypopituitarism such as craniopharyngiomas [7, 8,
11]. To our knowledge, only one existing non-adenomatous
case series has described endocrine outcomeswithout excluding
any histology subtypes, though it did not report on sellar en-
croachment or size characteristics [13]. Valassi et al. described
endocrine outcomes in a large cohort of non-adenomatous
lesions after an average follow-up of 42 months. Their rate of
deterioration in postoperative pituitary function was just 10%,
though their average follow-up was longer [13]. Pituitary func-
tion is known to recover with time after surgery [9].
Almost a fifth of our patients underwent a second surgical
procedure and the number of operations was not found to
significantly influence endocrine outcome. This is similar to
other reports studying pituitary adenomas. For example, Rim
et al. described postoperative endocrine status in 29 patients
with non-functioning pituitary adenomas undergoing redo
surgery. None had worsened endocrine outcomes after
3.6 years average follow-up [10].
We found that the extent of the preoperative sellar en-
croachment as determined by the sellar encroachment score
was predictive of the need for pre- as well as postoperative
pituitary hormone replacement. The effect was independent of
histology, lesion volume, surgical approach (i.e. cranial versus
trans-sphenoidal route) and extent of resection, which did not
influence endocrine outcome in multivariate analysis. This is a
novel finding. Similar observations have been made in studies
investigating pituitary adenomas. Thus, Berkmann et al. de-
scribed 60 patients with non-functioning pituitary adenomas
and found that those with a greater degree of sellar invasion as
assessed by the Hardy grade were more likely to develop
postoperative hypopituitarism. The effect was independent
of tumour volume [1].
We acknowledge a number of limitations in the present
study. We have determined pituitary function by the need
for hormone replacement rather than objective measure-
ment of pituitary hormone levels or assessment of patient
symptomatology. This could have underestimated the true
Fig. 2 The association between the sellar encroachment score and need
for pituitary hormone replacement pre- (a) and postoperatively (b) (N =
117). The grey bar in panel a (i.e. preop group) represents the proportion
of patients requiring pituitary hormone replacement preoperatively. The
black bar in panel b (i.e. postop group) represents the proportion of
patients with new additional pituitary hormone replacements postopera-
tively. Pre- (a) and postoperatively (b) there was increased need for pitu-
itary hormone replacement with increasing sellar encroachment scores
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rate of hypopituitarism, though arguably gives a more clin-
ically meaningful result. We also assumed that new postop-
erative hormone requirements were entirely due to primary
hypopituitarism. Other potential causes such as hypotha-
lamic dysfunction, as may arise iatrogenically from surgery,
were not considered. Moreover, the temporal pattern of en-
docrine recovery was not assessed as it is beyond the scope
of this study.
Conclusions
In this study, we describe the risk factors for the need for pre-
and postoperative pituitary hormone replacements in one of
the largest cohort of patients with non-adenomatous sellar/
parasellar lesions in the literature. Around a quarter (26%)
required pituitary hormone replacement preoperatively, and
35% required new pituitary hormone replacements postoper-
atively. We describe a novel score to quantify the degree of
sellar encroachment in two imaging planes—the sellar en-
croachment score, which was the only factor predictive of
pituitary endocrine outcome both pre- and postoperatively
and before adjuvant radiotherapy. Existing literature on non-
adenomatous sellar pathology is limited and our findings re-
quire future validation.
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